Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add filters

Database
Document Type
Year range
1.
Curr Med Chem ; 29(4): 635-665, 2022.
Article in English | MEDLINE | ID: covidwho-1742086

ABSTRACT

Due to its fast international spread and substantial mortality, the coronavirus disease COVID-19 evolved to a global threat. Since there is currently no causative drug against this viral infection available, science is striving for new drugs and other approaches to treat the new disease. Studies have shown that the cell entry of coronaviruses into host cells takes place through the binding of the viral spike (S) protein to cell receptors. Priming of the S protein occurs via hydrolysis by different host proteases. The inhibition of these proteases could impair the processing of the S protein, thereby affecting the interaction with the host-cell receptors and preventing virus cell entry. Hence, inhibition of these proteases could be a promising strategy for treatment against SARSCoV- 2. In this review, we discuss the current state of the art of developing inhibitors against the entry proteases furin, the transmembrane serine protease type-II (TMPRSS2), trypsin, and cathepsin L.


Subject(s)
COVID-19 , SARS-CoV-2 , COVID-19/drug therapy , Humans , Serine Proteases , Spike Glycoprotein, Coronavirus/metabolism , Virus Internalization
2.
Biospektrum (Heidelb) ; 27(3): 254-256, 2021.
Article in German | MEDLINE | ID: covidwho-1384644

ABSTRACT

The SARS-CoV-encoded papain-like cysteine protease (PLpro) plays crucial roles in viral replication and maturation processes. It is required to cleave the precursor polyproteins into functional proteins. Thus, it is considered to be a promising target for developing specific drugs. For rational optimization of hit compounds, information about the structure-activity relationship (SAR) is fundamental. Herein, we characterize isoindolines as a new class of PLpro inhibitors.

3.
Curr Med Chem ; 29(4): 635-665, 2022.
Article in English | MEDLINE | ID: covidwho-1247734

ABSTRACT

Due to its fast international spread and substantial mortality, the coronavirus disease COVID-19 evolved to a global threat. Since there is currently no causative drug against this viral infection available, science is striving for new drugs and other approaches to treat the new disease. Studies have shown that the cell entry of coronaviruses into host cells takes place through the binding of the viral spike (S) protein to cell receptors. Priming of the S protein occurs via hydrolysis by different host proteases. The inhibition of these proteases could impair the processing of the S protein, thereby affecting the interaction with the host-cell receptors and preventing virus cell entry. Hence, inhibition of these proteases could be a promising strategy for treatment against SARSCoV- 2. In this review, we discuss the current state of the art of developing inhibitors against the entry proteases furin, the transmembrane serine protease type-II (TMPRSS2), trypsin, and cathepsin L.


Subject(s)
COVID-19 , SARS-CoV-2 , COVID-19/drug therapy , Humans , Serine Proteases , Spike Glycoprotein, Coronavirus/metabolism , Virus Internalization
SELECTION OF CITATIONS
SEARCH DETAIL